Lyt til artiklen
Lundbeck has raised its revenue forecast for 2009 following a positive first quarter that has surprised analysts.
The company has announced its highest ever quarterly revenue of DKK 3,226 million, a growth of 15 percent and says the result is ‘driven by strong growth in Cipralex, Ebixa and Azilect and with the divestment of LifeCycle Pharma contributing DKK 124 million to first quarter revenue’.
